PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Iodohippurate→

Iodohippurate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
147-58-0
Molecular formula
C9H8INO3
Molecular weight
305.07 g/mol
Drug class
Diagnostic radiopharmaceuticalrenal tubular secretion and effective renal plasma-flow imaging agent when radioiodinated
Mechanism of action
Radioiodinated orthoiodohippurate is cleared predominantly from the circulation by active secretion through organic anion transporters in the proximal renal tubules, with a smaller contribution from glomerular filtration. Renal uptake and clearance are measured by scintigraphy.
Indications / reported uses
  • Dynamic renal scintigraphy to assess renal perfusion, effective renal plasma flow, tubular extraction and urinary drainage in selected diagnostic protocols.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6020824/ · https://sites.snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2018/Renal%20Scintigraphy_Blaufox_0318.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Iodohippurate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iodohippurate Permitted Daily Exposure (PDE) report (the Iodohippurate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iodohippurate Occupational Exposure Limit (OEL) report (the Iodohippurate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.